Brief: Armata Pharmaceuticals Announces $15 Mln Award From The U.S. Department Of Defense
17/06/2020 12:41
June 17 (Reuters) - Armata Pharmaceuticals Inc ARMP.A :
* ARMATA PHARMACEUTICALS ANNOUNCES $15 MILLION AWARD FROM
THE U.S.
DEPARTMENT OF DEFENSE (DOD) FOR DEVELOPMENT OF BACTERIOPHAGE
THERAPY TO TREAT S. AUREUS BACTEREMIA INFECTIONS
* ARMATA PHARMACEUTICALS - NON-DILUTIVE FUNDING TO BE USED
TO
ADVANCE SECOND PHAGE-BASED THERAPEUTIC CANDIDATE IN A PHASE 1B/2
CLINICAL STUDY
* ARMATA PHARMACEUTICALS INC - PRIMARY OBJECTIVES OF PHASE
1B/2
BACTEREMIA STUDY WILL BE TO EVALUATE SAFETY AND TOLERABILITY OF
AP-SA02 AS AN ADJUNCT
* ARMATA PHARMACEUTICALS INC - DOES NOT BELIEVE CLINICAL
TRIAL OF
BACTEREMIA STUDY WILL INITIATE PRIOR TO MID-2021
* ARMATA PHARMACEUTICALS INC - CLINICAL TRIAL OF AP-PA02
TARGETING
PSEUDOMONAS AERUGINOSA IS ON TARGET TO ENROLL LATER IN YEAR
Source text for Eikon: ID:nPn1W7DKSa
Further company coverage: ARMP.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Armata Pharmaceuticals
See all newsBrief: Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Delays Announcement Of Fourth Quarter And Full-Year 2025 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation
Armata Pharma jumps on US FDA nod for late-stage infection trial
Brief: Armata Pharmaceuticals Commissions cGMP Manufacturing Facility In Los Angeles